Biopharmaceutical company Mabwell has announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821).

Boehringer Ingelheim has licensed Synaffix B.V.’s ADC technology, significantly bolstering its ADC portfolio with the goal of ...

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has extended its collaboration with ...

Are you prepared for what’s next in DSCSA compliance?

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over these assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic ...

Essex Management, an Emmes Group company, has appointed David Loose as Chief Executive Officer (CEO), effective immediately.

The companies entered the agreement in 2023 to jointly advance as many as 11 drug programs, mainly targeting cardiovascular ...

Increases speed to market for drug developers working on nucleic acid therapeutics.

Mytos, a provider of automated cell manufacturing, has entered a manufacturing collaboration with Aspen Neuroscience, Inc. to ...

Mytos has entered into a manufacturing collaboration with Aspen Neuroscience Inc. to automate the manufacturing of autologous ...